These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 20461751)
1. Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer. Kim S; Cho H; Nam EJ; Kim SW; Kim YT; Park YW; Kim BW; Kim JH Genes Chromosomes Cancer; 2010 Jul; 49(7):585-95. PubMed ID: 20461751 [TBL] [Abstract][Full Text] [Related]
2. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537 [TBL] [Abstract][Full Text] [Related]
3. Proteomic identification of autoantibodies in sera from patients with ovarian cancer as possible diagnostic biomarkers. Yoneyama K; Kojima S; Kodani Y; Yamaguchi N; Igarashi A; Kurose K; Kawase R; Takeshita T; Hattori S; Nagata K Anticancer Res; 2015 Feb; 35(2):881-9. PubMed ID: 25667470 [TBL] [Abstract][Full Text] [Related]
4. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer]. Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769 [TBL] [Abstract][Full Text] [Related]
5. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Fujita Y; Nakanishi T; Hiramatsu M; Mabuchi H; Miyamoto Y; Miyamoto A; Shimizu A; Tanigawa N Clin Cancer Res; 2006 Nov; 12(21):6415-20. PubMed ID: 17085654 [TBL] [Abstract][Full Text] [Related]
6. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419 [TBL] [Abstract][Full Text] [Related]
7. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157 [TBL] [Abstract][Full Text] [Related]
8. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Fujita Y; Nakanishi T; Miyamoto Y; Hiramatsu M; Mabuchi H; Miyamoto A; Shimizu A; Takubo T; Tanigawa N Cancer Lett; 2008 May; 263(2):280-90. PubMed ID: 18334280 [TBL] [Abstract][Full Text] [Related]
9. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer. Barua A; Bradaric MJ; Kebede T; Espionosa S; Edassery SL; Bitterman P; Rotmensch J; Luborsky JL Am J Reprod Immunol; 2007 Apr; 57(4):243-9. PubMed ID: 17362385 [TBL] [Abstract][Full Text] [Related]
10. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Tammela J; Jungbluth AA; Qian F; Santiago D; Scanlan MJ; Keitz B; Driscoll D; Rodabaugh K; Lele S; Old LJ; Odunsi K Cancer Immun; 2004 Oct; 4():10. PubMed ID: 15487888 [TBL] [Abstract][Full Text] [Related]
11. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. Desmetz C; Bibeau F; Boissière F; Bellet V; Rouanet P; Maudelonde T; Mangé A; Solassol J J Proteome Res; 2008 Sep; 7(9):3830-7. PubMed ID: 18683965 [TBL] [Abstract][Full Text] [Related]
12. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284 [TBL] [Abstract][Full Text] [Related]
13. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085 [TBL] [Abstract][Full Text] [Related]
14. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Kim JH; Herlyn D; Wong KK; Park DC; Schorge JO; Lu KH; Skates SJ; Cramer DW; Berkowitz RS; Mok SC Clin Cancer Res; 2003 Oct; 9(13):4782-91. PubMed ID: 14581349 [TBL] [Abstract][Full Text] [Related]
15. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]. Zhao Q; Duan W; Wu YM; Qian XH; Deng XH Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805 [TBL] [Abstract][Full Text] [Related]
16. LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker. He Y; Wu X; Liu X; Yan G; Xu C J Proteome Res; 2010 Dec; 9(12):6180-90. PubMed ID: 21028892 [TBL] [Abstract][Full Text] [Related]
17. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682 [TBL] [Abstract][Full Text] [Related]
18. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer. Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955 [TBL] [Abstract][Full Text] [Related]
19. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Hong SH; Misek DE; Wang H; Puravs E; Giordano TJ; Greenson JK; Brenner DE; Simeone DM; Logsdon CD; Hanash SM Cancer Res; 2004 Aug; 64(15):5504-10. PubMed ID: 15289361 [TBL] [Abstract][Full Text] [Related]
20. Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer. Li J; Wang LJ; Ying X; Han SX; Bai E; Zhang Y; Zhu Q Scand J Immunol; 2012 Mar; 75(3):342-9. PubMed ID: 22010875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]